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Abstract

BACKGROUND: Breast cancer is the most common cancer in Pakistani women. We report the presenting features, treatment patterns and

survival of breast cancer from a University Hospital in Southern Pakistan and compare the data with international population based studies.
MATERIALS AND METHODS: Medical records of patients diagnosed to have breast cancer between January 1999 and November 2008 were
reviewed retrospectively. RESULTS: A total of 845 patients were identified. Median age of diagnosis was 48 years (range 18‑92). Clinical stage was
as follows: Stage I 9.9%; Stage II 48.5%; Stage III 26.2%; Stage IV 13.8%; data not available 1.5%. Approximately, half (51.6%) were estrogen
receptor (ER) positive and 17.5% over‑expressed Her2/neu. Nearly 23% patients received neo‑adjuvant chemotherapy while 68.9% received
adjuvant chemotherapy. Anthracycline based treatment was the most common treatment until 2003 while later on, patients also received taxanes
and trastuzumab based therapy. Age, stage, tumor size, lymph node status, tumor grade, ER status, treatment with hormonal therapy and radiation
were the major predictive factors for overall survival (OS). We report an impressive 5 year OS of 75%, stage specific survival was 100%, 88%
and 58% for Stages I, II and III respectively. CONCLUSION: The majority of patients present at a younger age and with locally advanced disease.
However, short term follow‑up reveals that the outcomes are comparable with the published literature from developed countries. Long‑term follow‑up
and inclusion of data from population‑based registries are required for accurate comparison.
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Introduction
Breast cancer remains the leading cause of cancer diagnosis
and cancer‑related death in women, world‑wide. Mortality
from breast cancer in the western hemisphere has recently
showed a trend of decline, understandably this being a
result attributable to effective screening and early detection
programs, health awareness, access to health‑care and a
better health‑care infrastructure. Developing world has on
the other hand shown an increasing mortality, perhaps as
a result of lack of availability of factors mentioned for the
west, as well increasing “westernization” of the life‑style.[1]
De novo geographical factors are also considered to be an
important contributor for outcomes from breast cancer.
The incidence of breast cancer varies almost 10 fold if data
were compared from different countries.[2] Comparison of
breast cancer data from various geographic locations is also
considered to be important to understand underlying causes
of disease or the reasons of death.[3]
Pakistan is a developing country, where health‑care access
is limited and fragmented. Population based registries
report the age‑standardized incidence of 9.1/100,000
for breast cancer, which is the highest reported from
the area and is considerably higher than the much more
populous neighboring India.[4] The Aga Khan university
Hospital is the largest private medical hospital, in the
country and is located in the city of Karachi in Southern
Pakistan. It receives patients from all over the country.[4] The
comprehensive cancer care services make it a reliable cancer
care center in the country.[5]
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This report covers different aspects of breast cancer
observed at our institution, from demographic features,
histopathological subtypes, treatment modalities, patterns
and incidence of relapse and the treatment strategies in the
metastatic setting, as well as the survival.
Materils and Methods
Data were analyzed retrospectively. The diagnoses are stored
electronically using international classification of diseases
version 9/10. Clinical data on consecutive patients admitted
to the hospital between January 1999 and November
2008 and diagnosed to have invasive breast cancer were
retrieved. Patients who were diagnosed with the disease
earlier, but experienced relapse during the study period
were also included. The hospital is one of the few hospitals
providing comprehensive cancer care (surgery, chemotherapy,
radiotherapy, palliative care, screening and molecular testing)
in Pakistan. Majority of the patients included were diagnosed
and treated at our hospital. For patients who had been
initially diagnosed elsewhere, all specimens were reviewed
by the pathology department for verification of diagnosis,
immunohistochemistry (IHC) for estrogen receptor (ER),
progesterone (PR) and Her2/neu status or fluorescence
in situ hybridization (FISH) for Her2/neu gene, where
indicated.
The medical records of all patients with a diagnosis of
invasive breast cancer were reviewed and information
was extracted on to a pre‑designed database. Variables
included age, gender, date of diagnosis, side of involvement;
histopathological type of tumor; tumor size (clinical and
pathological), lymph node involvement; number of lymph
nodes removed, tumor grade, lymphovascular invasion,
ER status, PR status, and Her2/neu status. Clinical and
pathological stages were determined using the 6th edition of
American Joint Committee on Cancer (AJCC) manual. The
date of last follow‑up exam, date and site of relapse and date
of death, when relevant were also recorded. The relapses
were confirmed from the hospital records and during patient
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follow‑up in clinics (not described for patients who lost to
follow‑up) and death was also confirmed either form the
hospital records or through phone calls.
The data were censored at the date of last follow‑up
exam for each patient and relapse‑free survival (RFS)
was calculated from the date of diagnosis to the date of
documented relapse. Overall survival (OS) was calculated
from the date of diagnosis to the date of death or last
follow‑up/death where relevant. OS and RFS were
determined using the method of Kaplan and Meir; Cox
proportional hazard model was used to compare the survival
between different stages. Univariate analysis was performed
using the Chi‑square test. The Cox model was used for
multivariate analysis including all statistically significant
factors on univariate analysis. Data were analyzed on
statistical software package Statistical Package for the Social
Sciences (version 16.0.2, SPSS, Chicago, IL, USA).

Table 1: Clinical features of all patients treated
during January 1999 to November 2008
Clinical characteristics

Number (%)

Gender
Female
Male
Age
<40
46‑60
>60
Menopausal status
Pre‑menopausal
Menopausal
Involved side
Left
Right

843 (99.8)
2 (0.2)
178 (21.1)
515 (60.9)
152 (18)
386 (45.7)
459 (54.3)
427 (50.5)
393 (46.5)

Bilateral

25 (3)

Results
Clinical features

A total of 845 patients were included diagnosed to
have breast cancer in the study period while remaining
10 patients were diagnosed earlier, but included in the
study as they received treatment for disease relapse. All
but two were females; the median age at the diagnosis
was 48 years (range 18‑92 years). The majority of patients
were between the ages 40 and 60 years (n = 515, 60.9%),
15% had a family history of breast cancer, 45.7% of
all patients were pre‑menopausal while remaining had
achieved menopause prior to diagnosis. Almost half of the
patients (50.5%) had left‑sided breast cancer [Table 1].
Pathological features

Clinical and pathological stages are summarized in Table 2.
Merely 9.9% patients presented with clinical Stage I
disease (according to AJCC manual, 6th edition), clinically,
T4 disease was detected in 21.1% patients; only 12.1%
of patients presented with clinical T1 lesion at the time of
diagnosis. Likewise, 43.5% patients had clinically palpable
nodes. Pathologically mean tumor size was 4.11 cm [Table 2].
Microscopically, 42.1% patients had involved lymph nodes,
the mean number of involved nodes was 6 (range 0‑33).
More than 93% of the patients had infiltrating ductal
carcinoma as the pathological diagnosis, while infiltrative
lobular carcinoma (2.7%) was the next common type. Almost
a quarter (25.9%) of patients had poorly differentiated cancer
and lymphovascular invasion was seen in 15.1% specimens.
ER status was expressed by 51.6% tumors, whereas, PR was
expressed by 44%. Data on HER‑2/neu status was available
for 488 (57.7%) patients; 13.1% patients expressed the
protein using the IHC method, whereas, for another (4.5%)
patients the gene could be detected using FISH, leading to
an overall expression rate of 17.6%. Triple negative disease
was diagnosed for 130 (15.3%) patients [Table 3].
For patients presenting with Stage IV disease at
presentation (n = 117, 13.8%), bone was the most
common site of distant disease (n = 74, 63.2%), followed
by lungs (n = 40, 34.1%); more than one organ was
involved in 34 patients (29.0%).
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Table 2: Clinical and pathological stage of all
patients
Disease/tumor
charechtarestic
Primary tumor
Tis
T0
T1
T2
T3
T4
NA*
Node status
N0
N1
N2
N3
NA*
Overall stage
0
I
II
III
IV
NA*

Clinical
stage n (%)

Pathological
stage n (%)

‑
‑
102 (12.1)
360 (42.6)
173 (20.5)
185 (21.9)
25 (3)

1 (0.1)
26 (3.1)
178 (21.1)
374 (44.3)
93 (11.0)
67 (7.9)
106 (12.6)

441 (52.2)
274 (32.4)
86 (10.2)
8 (0.9)
36 (4.3)

365 (43.2)
178 (21.1)
97 (11.5)
80 (9.5)
125 (14.8)

‑
84 (9.9)
410 (48.5)
221 (26.2)
119 (14.1)

23 (2.8)
110 (13.0)
355 (42.0)
215 (25.4)
‑

11 (1.3)

27 (3.2)

*Data missing or not applicable

Treatment

Of all patients with localized or locally advanced disease at
presentation (n = 728, 86.2%), 502 (68.9%) were treated
with adjuvant chemotherapy. For patients who presented
with metastatic disease (n = 117, 14.1%), palliative
chemotherapy or hormonal therapy was administered to
95 (81.2%) patients, 37 patients declined chemotherapy
while four patients moved from the hospital before the
initiation of treatment.
Out of 728 patients with non‑metastatic disease on
presentation, 265 (36.4%) patients had locally advanced
disease (cT3 or positive nodes clinically) and 195 (73.5%)
of these were treated with neo‑adjuvant chemotherapy.
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Almost 2/3 of patients (61.9%) had modified radical
mastectomy (MRM), while breast conservation surgery was
performed in 21.2% and 5.1% were treated with simple
mastectomy because of symptomatic advanced disease. Of
179 patients who had breast conservation surgery only
34 patients were administered neo‑adjuvant chemotherapy,
while out of 523 patients who had MRM 130 were treated
with neo‑adjuvant chemotherapy.
Majority of patients were treated with anthracycline based
regimen (n = 500, 59.1%) while 203 (24.0%) received a
taxane in addition to other cytotoxics. Amongst 149 patients
expressing Her2/neu (by IHC or FISH), only 41 patients
received trastuzumab [Table 4]. Only 24 patients completed
one calendar year of treatment. Most declined and discontinued
the treatment per cost of therapy. A total of 528 (62.5%)
patients were treated with radiation, in the adjuvant setting.
Hormonal agents were prescribed to 450 (53.2%) patients,
tamoxifen was the most commonly prescribed drug (n = 357,
79.3%), anastrozole, letrozole and exemestane were prescribed
to 54, 38 and one patients respectively. Most of the
patients (n = 273, 60.6%) are/were taking their hormonal
therapy actively until the date of last follow‑up, 71 (15.7%)
have completed their 5 years of hormonal treatment, while
remaining patients were switched to other hormonal agent or
chemotherapy due to relapse, progressive disease, complication,
intolerance, to extended aromitase inhibitors, or as switched
therapy after 2‑3 years of tamoxifen.
Relapse patterns and survival

All patients were followed at regular intervals in clinics,
until the time of death or until they lost to follow‑up with
median follow‑up of 29 months (range 1‑224 months).
135 (135/728 = 18.5%) patients experienced relapse (local,
loco‑regional or distant). Distant recurrence was documented
in 69 (9.5%) while 22 (3.0%) had a local recurrence.
Bone, lungs and brain were the main sites of relapse.
Most of the patients were treated with chemotherapy
or radiotherapy while some patients were treated with
combination treatment [Table 5]. Of all patients treated for
relapsed disease, 32 progressed, 12 had a partial response,
Table 3: Receptor status for all patients
Receptor status
Estrogen receptor positive
Estrogen receptor negative
Estrogen receptor N/A
Progesterone receptor positive
Progesterone receptor negative
Progesterone N/A
Her2/neu status (by IHC)
Her2/neu 3+
Her2/neu 2+
Her2/neu negative/not done
Her2/neu status (by FISH)
Her2/neu positive
Her2/neu negative
Her2/neu not done

Median RFS was 34 months while 5 year RFS was 19%.
Hormone receptor status P = 0.05), Her2/neu (P ≤ 0.01),
tumor size (clinical or pathological [P ≤ 0.01]),
clinical node status (P = 0.002), clinical stage at
presentation (P ≤ 0.01), number of involved nodes on
pathological examination (P = 0.02), administration of
neo‑adjuvant and adjuvant chemotherapy, radiotherapy and
hormonal therapy (P ≤ 0.01 for each) were significant
contributory factors for RFS.
At the time of last follow‑up (July 31, 2010), 159 (18.8%)
patients have died due to disease, 26 (3.1%) to causes
not related to disease or treatment, 3 (0.4%) because of
treatment related toxicity. Median OS for all patients was
157 months with 5 year OS of 75%, while it was 100%,
88% and 58% for Stages I, II and III respectively. Median
survival for Stage IV patients was 18 months [Figure 1].
Stage at presentation (P ≤ 0.01), clinical and pathological
tumor size (P ≤ 0.01), clinical and pathological node
status (P ≤ 0.01), tumor grade (P ≤ 0.01), lymphovascular
invasion (P = 0.001), ER status (P = 0.02), radiation
therapy (P ≤ 0.01) and hormonal therapy (P ≤ 0.01) were
significant factors for OS on univariate analysis.
Clinical stage at presentation (P ≤ 0.01), pathological nodal
status (P ≤ 0.01), ER status (P ≤ 0.01) were significant
predictive factor for OS on multivariate analysis.
Discussion
The outcomes from breast cancer depend on multiple
factors. Breast cancer biology including clinical stage,
pathological subtype, hormonal and Her2/neu status are
major contributors. Personal factors such as age, body
mass index and race are also important. Socioeconomic
factors, such as, access to the health‑care, ability to afford
appropriate treatment and facilities for screening and
long‑term follow‑up and management are much less
addressed.[6]

n (%)
436 (51.6)
364 (43.1)
45 (5.3)
372 (44)
418 (49.5)
54 (6.4)
111 (13.1)
148 (17.5)
586 (69.3)
38 (4.5)
93 (11)
40 (4.7)

N/A=Not available; IHC=Immunohistochemistry; FISH=Fluorescent in situ
hybridization
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5 had minimal response and 4 had stable disease while 1
had a complete response. 11 patients were treated after
complete surgical removal of their relapsed disease and were
in remission until the last follow‑up.

Figure 1: Overall survival for all patients according to stage
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Table 4: Chemotherapy regimes
Intent/chemotherapy regimen
Neo‑adjuvant chemotherapy
AC
FAC/FEC
TAC
Taxane (paclitaxel or docetaxel)
after anthracycline
Trastuzumab*
Hormonal treatment
TCH
Adjuvant chemotherapy
AC
FAC/FEC
AC/FAC→paclitaxel
(3 weekly/dose dense/weekly)
TAC
CMF
AC/FAC→docetaxel
Taxane (paclitaxel or docetaxel)
(after anthracycline)
Trastuzumab (with or after taxane)

No. (%)
106 (12.5)
31 (3.6)
27 (3.2)
72 (8.5)
8 (0.9)
8 (0.9)
3 (0.4)
109 (12.8)
184 (21.7)
100 (11.8)
20 (2.3)
32 (3.7)
5 (0.5)
42 (4.9)
39 (4.6)

A=Doxorubicin; C=Cyclophosphamide; E=Epirubicin; F=Fluorouracil;
H=Trastuzumab; M=Methotrexate; T=Docetaxel; *With or without taxane

Table 5: Relapse patterns of patients
Relapse patterns
Site of relapse
Distant relapse
Local relapse
Contra lateral relapse
Loco‑regional relapse
Loco‑regional and distant relapse
Contra lateral and distant relapse
Relapse while on adjuvant chemotherapy
Site of first distant relapse
Bone
Lungs
Brain
Liver
Pleura
Bone+lung
Liver+lung+bone
Carcinomatous meningitis
Others

(n=728)
No. (%)
69 (9.5)
22 (3.0)
16 (2.2)
9 (1.2)
13 (1.8)
2 (0.2)
4 (0.6)
17 (12.59)
14 (10.37)
13 (9.62)
6 (4.4)
5 (3.7)
9 (6.6)
6 (4.4)
3 (2.2)
15 (11.1)

A comprehensive 10‑year data is presented from Southern
Pakistan. The data focuses on most common aspects of
concern in breast cancer. The series reveal a younger mean
age at presentation, i.e., 48 years as compared to 61 years
reported in the surveillance epidemiology and end results
(SEER) data.[7] Our data conform to the data from Karachi
cancer registry, a population based registry representing a
sample population from all parts of Pakistan, which showed
that more than 60% of breast cancer patients were below
50 years[8] and other studies reported form the country and
surprisingly the age at presentation has remained almost same
in last few decades.[9‑11] The age distribution curve is also
similar to the data from most neighboring countries, including
Indian Journal of Cancer | April–June 2016 | Volume 53 | Issue 2

those from Arabian peninsula[12] and the east Asia.[13] A small
number of patients (9.9%) presented with Stage I disease,
while nearly half (48.5%) had Stage II disease, which seems
to be similar with SEER data; where 60% of patients are
diagnosed to have the localized disease, but differs widely in
advanced stage disease as 5% patients had Stage IV disease
at presentation in SEER data as compared to 14.1% in our
study. This highlights the changes in the trends perhaps set by
screening programs and early stage detection.[14,15] A diagnosis
at an early stage is a strong negative predictor of recurrence
and therefore improves the long‑term survival.[9,16]
The number of patients presenting with Stage IV disease
in our study were more than double compared with the
western literature (14% vs. 5%). Even for patients with
non‑metastatic disease a significant number had advanced
tumor size (T4 lesions). Once staged our patients did not
show vastly different pattern in terms of number and size
of the lymph nodes involved and with the mean number of
lymph nodes involved when compared with data presented
by Carter et al. [17] In comparison to contemporary data
the hormone receptor status was found to be lower in our
population with over half of all patient’s tumors expressed
ER, whereas, 44% expressed PR receptors.
Most of our patients underwent MRM, with trends for breast
conserving surgery relatively underutilized in most clinical
situations which reflects the same trend in other institutions
offering breast cancer surgery in the country.[11,18] A high success
rate for sentinel lymph node biopsy has been previously reported
from our institute already.[19]
Neo‑adjuvant chemotherapy was effectively utilized in almost
three quarters of patients with locally advanced disease.
A combination of adriamysin and cyclophohomide (AC) was
the most commonly used chemotherapy regimen. Less than
3.6% of the patient received epirubicin. The reasons remain
speculative; however, slightly higher unit cost compared to
doxorubicin may have contributed. Not all patients could afford
taxane based chemotherapy. Close to 24% managed to get a
taxane combination when it was required either in the adjuvant
or in the metastatic setting. Trastuzumab is now considered
as an integral part of management regimen in Her2/neu over
expressing breast cancers. A majority of our patients however
could not afford to take adjuvant trastuzumab and in fact a very
few actually received the drug for 1 year in the adjuvant setting.
Financial difficulties leading to inability to receive standard
adjuvant treatment affects the OS in developing countries, or
where there is a lack of widespread health insurance system.
Tamoxifen was the most favored hormonal agent prescribed.
Regardless of the menopausal status, a trend which is consistent
with practice observed by physicians world‑wide and reported
by us previously. [20] Our patients showed a 3% over all
incidence of local relapse compared to international report of
5% as reported in National Surgical Adjuvant Breast and Bowel
Project NSABP‑04 for adequately treated patient, with matching
figures for distant recurrences as well.[21] In our data series on a
10 year follow‑up breast cancer, survival rates match the survival
rates reported internationally and regionally [Figure 1].[21,22]
The data presented has limitations, including a possible
inherent bias of being from a single institution; it
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nevertheless represents a significant contribution as south
Karachi, our sample population, is considered to be the
habitat of a population representative of the whole of the
country of Pakistan.[23] Although the data presented here,
may not be a complete representation of the prevailing
trends of breast cancer in Pakistan, it however should
contribute immensely to the existing scarce information on
patterns and trends of the population from the subcontinent.
The fact that the data set is perhaps the largest coming out
from any single institution in Pakistan, makes it distinct. The
patterns that have come to light by this study highlight the
needs of further large scale population based studies to be
done so that cost‑effective guidelines on breast cancer care
are made specific to the needs of this population.
Though the World Health Organization has mentioned
about the age distribution of cancer for Pakistan and
available cancer treatment facilities it does not mention the
outcome at large and our data may help to establish or
provide a platform for implementation of the guide lines for
the breast cancer treatment in the country, but may also help
to focus on the population screening in future.[24]
It should also be noted that our institution plays key role in
cancer registry through its wide laboratory network across
the country through, which large number of pathology
specimen are sent to the pathology laboratory, which help
to assess the cancer burden in the country.[4]

5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

16.

Conclusion

17.

In conclusion, this data set presented from a 10 years
follow‑up of breast cancer patients at our institute suggests
that breast cancer appears at relatively younger age and
relatively advanced stage of the disease. The pathologic
and biologic parameters show some distinct patterns from
the region. Treatment modalities offered are according to
the internationally accepted standards, but affordability
and availability of the same remains restricted for most
population. Despite these factors an overall trend of
matching survival are found in comparison to regional and
international data with regards to survival, however further
large scale studies and comparative analysis are needed to
improve the assessment of epidemiological and survival
trends of our population.

18.
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